In order to better understand the incomplete response of EGFR-mutant NSCLC to EGFR TKI as well as identify prospective mechanisms of resistance, we conducted a genome-scale CRISPR-Cas9 genetic screen in a human NSCLC cell line harbouring activating EGFR mutation. Here, EGFR is linked to non-small cell lung carcinoma.